the "bolt on" acquisition ideal for Roche is Helicos. Roche did say on announcing the original Illumina bid they were interested in" bolt-on acqusitions "in the field of single molecule and direct RNA sequencing after the bid had gone through..they are no saying the same thing..same wording. There is only 1 platform on the market that has that technical capability...the Helicoscope. Fact
b-bear, you have been trying to prop up this dead horse for months. Their IP is flawed, the instrument is huge and can not be sold for money, and they have no leadership. Roche could have bought them for pocket change, but they didn't because they are not even worth the effort as evidenced by the fact that they did not get an offer. Can you move on?
How many Helioscopes have been sent to locations where Helicos was actually paid? How many are currently being "used"? Montly consumables are generating how much revenue? How many units have been sent back to the company?
I have never argued Helicos was a commercial success..it could never have been with Illumina present. ..but the technology is outstanding . The only true single molecule sequencing platform capable of direct RNA sequencing. In the right hands (Illumina, Roche , Pfizer whoever..) the platform is capable of huge strides in drug discovery ( articularly cancer genomics).. that is why Roche speicically mentioned they wanted Single Molecule technology post an Illumina takeover. Unfortunately for the Illumina mafia , Helicos is not going away....and may just prove to be a spanner in the works with Roche now on the scene.